341,659 Shares in CeriBell, Inc. $CBLL Acquired by Peregrine Capital Management LLC

Peregrine Capital Management LLC bought a new position in shares of CeriBell, Inc. (NASDAQ:CBLL) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 341,659 shares of the company’s stock, valued at approximately $6,399,000. Peregrine Capital Management LLC owned approximately 0.95% of CeriBell as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. KLP Kapitalforvaltning AS acquired a new position in CeriBell during the 1st quarter worth approximately $36,000. New York State Common Retirement Fund acquired a new position in CeriBell during the 1st quarter worth approximately $67,000. Quantbot Technologies LP acquired a new position in CeriBell during the 1st quarter worth approximately $175,000. Rhumbline Advisers boosted its position in CeriBell by 26.5% during the 1st quarter. Rhumbline Advisers now owns 15,629 shares of the company’s stock worth $300,000 after acquiring an additional 3,276 shares during the last quarter. Finally, Nuveen LLC acquired a new position in CeriBell during the 1st quarter worth approximately $311,000.

Insiders Place Their Bets

In related news, CTO Raymond Woo sold 11,112 shares of the stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $12.54, for a total value of $139,344.48. Following the sale, the chief technology officer owned 167,704 shares in the company, valued at approximately $2,103,008.16. This represents a 6.21% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 20.10% of the company’s stock.

CeriBell Stock Performance

NASDAQ CBLL opened at $12.89 on Tuesday. The company has a market cap of $472.60 million and a PE ratio of -4.31. The company has a current ratio of 13.31, a quick ratio of 12.91 and a debt-to-equity ratio of 0.11. CeriBell, Inc. has a 12 month low of $10.01 and a 12 month high of $32.75. The stock has a 50 day moving average of $12.07 and a 200-day moving average of $14.73.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.02. CeriBell had a negative return on equity of 48.42% and a negative net margin of 63.83%.The business had revenue of $21.20 million for the quarter, compared to analysts’ expectations of $20.52 million. CeriBell has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Analyst Ratings Changes

CBLL has been the subject of a number of recent research reports. Raymond James Financial initiated coverage on CeriBell in a research report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price target for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CeriBell in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, CeriBell currently has a consensus rating of “Moderate Buy” and an average price target of $30.50.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.